Cogent Biosciences (COGT) Enterprise Value (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Enterprise Value data on file, last reported at -$866.4 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 252.67% year-over-year to -$866.4 million in Q1 2026; TTM through Mar 2026 was -$866.4 million, a 252.67% decrease from a year earlier, with the FY2025 full-year figure at -$900.8 million, down 213.77% from the prior year.
• Enterprise Value for Q1 2026 stood at -$866.4 million, up from -$900.8 million in the prior quarter.
• Over the last five years, Enterprise Value for COGT reached as high as -$141.1 million in Q4 2022 and fell as low as -$900.8 million in Q4 2025.
• Historically, Enterprise Value has averaged -$355.7 million across 5 years, with a median of -$289.1 million in 2022.
• Across the five-year window, Enterprise Value surged 43.62% in 2025 and tumbled 252.67% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$141.1 million in 2022, then plunged by 88.26% to -$265.7 million in 2023, then slipped by 8.04% to -$287.1 million in 2024, then plunged by 213.77% to -$900.8 million in 2025, then climbed by 3.82% to -$866.4 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$866.4 million in Q1 2026, -$900.8 million in Q4 2025, and -$390.9 million in Q3 2025.